Lion Biotechnologies, Inc. (NASDAQ:IOVA)‘s stock had its “buy” rating restated by investment analysts at FBR & Co in a research report issued on Wednesday, October 25th. They currently have a $17.50 target price on the biotechnology company’s stock. FBR & Co’s target price would indicate a potential upside of 117.39% from the company’s current price. FBR & Co also issued estimates for Lion Biotechnologies’ Q3 2017 earnings at ($0.30) EPS, Q4 2017 earnings at ($0.30) EPS, FY2017 earnings at ($1.22) EPS, Q1 2018 earnings at ($0.34) EPS, Q2 2018 earnings at ($0.34) EPS, Q3 2018 earnings at ($0.34) EPS, Q4 2018 earnings at ($0.34) EPS, FY2018 earnings at ($1.36) EPS, FY2019 earnings at ($1.35) EPS, FY2020 earnings at ($1.07) EPS and FY2021 earnings at ($0.34) EPS.
A number of other research firms have also recently issued reports on IOVA. HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of Lion Biotechnologies in a research report on Thursday, August 31st. Oppenheimer Holdings, Inc. set a $13.00 price target on Lion Biotechnologies and gave the company a “buy” rating in a research note on Thursday, October 12th. Zacks Investment Research raised Lion Biotechnologies from a “hold” rating to a “buy” rating and set a $8.25 price target on the stock in a research note on Tuesday, October 17th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $11.00 price target on shares of Lion Biotechnologies in a research note on Tuesday, September 5th. Finally, Chardan Capital reissued a “buy” rating on shares of Lion Biotechnologies in a research note on Thursday, September 7th. One analyst has rated the stock with a hold rating and ten have given a buy rating to the company. Lion Biotechnologies currently has an average rating of “Buy” and a consensus target price of $14.53.
Lion Biotechnologies (NASDAQ:IOVA) opened at $8.05 on Wednesday. Lion Biotechnologies has a 1 year low of $4.45 and a 1 year high of $8.60.
Lion Biotechnologies (NASDAQ:IOVA) last released its quarterly earnings data on Tuesday, October 31st. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). sell-side analysts predict that Lion Biotechnologies will post -1.37 EPS for the current fiscal year.
WARNING: This report was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was illegally copied and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2017/11/12/fbr-co-reiterates-buy-rating-for-lion-biotechnologies-inc-iova.html.
Several institutional investors have recently made changes to their positions in the business. Wells Fargo & Company MN increased its holdings in shares of Lion Biotechnologies by 44.2% in the third quarter. Wells Fargo & Company MN now owns 103,528 shares of the biotechnology company’s stock worth $801,000 after acquiring an additional 31,724 shares in the last quarter. Trexquant Investment LP bought a new stake in shares of Lion Biotechnologies in the third quarter worth about $307,000. JPMorgan Chase & Co. increased its holdings in shares of Lion Biotechnologies by 63.4% in the third quarter. JPMorgan Chase & Co. now owns 1,779,700 shares of the biotechnology company’s stock worth $14,059,000 after acquiring an additional 690,527 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in shares of Lion Biotechnologies during the third quarter worth about $133,000. Finally, SG Americas Securities LLC boosted its position in shares of Lion Biotechnologies by 385.3% during the third quarter. SG Americas Securities LLC now owns 50,295 shares of the biotechnology company’s stock worth $390,000 after buying an additional 39,931 shares during the period. Institutional investors own 66.64% of the company’s stock.
Lion Biotechnologies Company Profile
Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.
Receive News & Ratings for Lion Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lion Biotechnologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.